Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Discovery & Translation

Blood signature of organ aging; plus updates from Roche, Feldan, Rezo

BioCentury’s roundup of translational innovations

December 9, 2023 12:18 AM UTC

A team led by Teal Omics Inc. co-founder Tony Wyss-Coray at Stanford University described a machine learning method in Nature to estimate the age of organs using human blood plasma proteins originating in specific organs. The authors found that people with accelerated heart aging, as assessed by the method, have a 250% increased heart failure risk, while accelerated brain and vascular aging predicted Alzheimer’s disease progression as well as the current best blood-based biomarker for Alzheimer’s.

Roche (SIX:ROG; OTCQX:RHHBY), WuXi AppTec Co. Ltd. (Shanghai:603259; HKEX:2359) and Axxam S.p.A. described in Cell Chemical Biology a selective HCN1 inhibitor that enhanced working memory in rats without the cardiovascular effects observed with non-selective HCN inhibitors that also bind cardiac-expressed HCN isoforms 2/3/4...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article